Trial intelligence / Profile preview

Semaglutide in Schizophrenia with Metabolic Syndrome

NCT07770282Phase 3Not yet recruiting

Sponsor: AIIMS New Delhi
Start: Dec 2026
Primary completion: Jul 2030

Overview

Phase 3, randomised, double-blind trial in metabolic syndrome comparing Semaglutide with Placebo (2 arms). Primary endpoint: QResearch Cardiovascular Risk Prediction Algorithm Version 3 at 24 weeks. Planned start Dec 2026; status: not yet recruiting.

Drugs

semaglutide

Conditions

metabolic syndrome

Beyond the preview

Go deeper on NCT07770282.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT07770282.